Sector News

Roche buys German genomics group Signature

February 10, 2015
Life sciences
Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany.
 
The Potsdam-based firm is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests.
 
Roche says these tests have the potential to advance non-invasive treatment response monitoring for patients with cancer. Roland Diggelmann, head of its diagnostics unit, stated that biobanks play an important role in aiding translational research and the development of personalised therapies for patients.
 
He added that Signature “represents a unique bridge between high value cancer biobanks and next generation sequencing (NGS) assay development”. The German group will be integrated into Roche Sequencing Unit, which has grown through the recent acquisitions of Bina Technologies and Genia Technologies.
 
Financial terms have not been disclosed.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach